

Financial Tear Sheet

Corporate Profile

Paratek is developing and commercializing innovative antibacterial therapeutics based upon tetracycline chemistry. Paratek has used its expertise in microbial biology and tetracycline chemistry to create chemically diverse and biologically distinct small molecules derived from the tetracycline class of molecules. Paratek's two lead antibacterial product candidates are omadacycline and sarecycline. Omadacycline entered Phase 3 clinical development in June 2015. Sarecycline entered Phase 3 clinical development in December 2014.

Stock Information

PRTK (Common Stock)

Exchange	NASDAQ (US Dollar)
Price	\$24.05
Change (%)	▲ 0.30 (1.26%)
Volume	90,863
52 Week Low	\$9.80
Market Cap	\$667,656,571
Rolling EPS	-3.82
PE Ratio	N/A
Shares Outstanding	27,761,188

Data as of 10/17/17 1:08 p.m. ET



Recent Paratek Pharmaceuticals News & Events

10/06/17 - 8:01 a.m.

Phase 3 Optic Study Microbiology Data Demonstrate Omadacycline has Potent In vitro Activity Against Multiple Pneumonia Pathogens, Including Resistant Bacteria

10/06/17 - 8:01 a.m.

Consistent Efficacy and Safety Profile Observed in New Analyses of OASIS-1 Phase 3 Study of Omadacycline in Patients with Difficult to Treat Comorbid Conditions

10/02/17 - 4:01 p.m.

Paratek Announces Inducement Grants

Date

Title

10/17/17 12:00 p.m. ET **Paratek Pharmaceuticals Inc. Investor Day**

SEC Filings

Filing Date	Form
-------------	------

08/04/17	8-K
----------	-----

08/02/17	10-Q
----------	------

07/21/17	4
----------	---

07/21/17	4
----------	---

Management

Randy Brenner Senior Vice President -
Regulatory, Quality and
Technical Operations

Jason Burdette Vice President -
Technical Operations

Jeanne Jew Senior Vice President -
Business Development

Raj Padmanabhan Vice President -
Information Technology

Regina Paglia Senior Vice President -
Human Resources

Susan Perkins,
J.D. Vice President -
Intellectual Property

Evan Tzanis Senior Vice President -
Clinical Development &
Clinical Operations

Michael F. Bigham Chief Executive Officer
and Chairman of the
Board

Evan Loh, M.D. President, Chief
Operating Officer and
Chief Medical Officer

William Haskel General Counsel and
Corporate Secretary

Douglas W. Pagán Chief Financial Officer

Adam Woodrow Chief Commercial Officer

Data provided by Nasdaq. Minimum 15 minutes delayed.